大鼠失神经支配骨折修复的实验研究
摘要
目的研究强骨胶囊促进大鼠失神经支配骨折愈合的作用机理。
方法雄性SD大鼠,10%水合氯醛腹腔麻醉,在距坐骨结节0.5cm处切断坐骨神经,横形截断股骨中段,建立失神经支配骨折动物模型,造模成功后,将大鼠随机分为强骨胶囊大剂量组、强骨胶囊中剂量组、强骨胶囊小剂量组、丹参组和空白对照组,每组30只。强骨胶囊大剂量组,给予强骨胶囊180mg/kg/d灌胃,每日一次;强骨胶囊中剂量组,给予强骨胶囊90mg/kg/d灌胃,每日一次;强骨胶囊小剂量组,给予强骨胶囊45mg/kg/d;丹参组,给予丹参注射液40mg/kg/d,灌胃,每日一次;空白对照组,遭摸后不作处理。各组大鼠分别在术后1周、2周和3周取骨折中心上下各1cm全段股骨标本,测算骨痂体积。骨痂取材切片,常规HE染色,观察骨痂结构。NGF、BMP-2和bFGF免疫组织化学染色,凝胶成像分析系统计算每个视野阳性细胞数。检测血清Ca、P和ALP。
结果(1)骨痂体积测算结果:术后1周,各组骨折处均可见增粗。强骨胶囊大剂量组和强骨胶囊中剂量组骨痂体积值大于丹参组(P＜0.05)和空白对照组(P＜0.05),强骨胶囊小剂量组骨痂体积值大于空白对照组(P＜0.05)。术后2周,各组骨痂体积均有不同程度的增大。强骨胶囊大剂量组和强骨胶囊小剂量组骨折断端新生软骨量增多,骨痂外直径增生显著。强骨胶囊大剂量组骨痂体积明显大于丹参组(P＜0.01)、空白对照组(P＜0.01)和强骨胶囊小剂量组(P＜0.01),中剂量组骨痂体积明显大于空白对照组(P＜0.01)和丹参组(P＜0.05),强骨胶囊小剂量组大于丹参组(P＜0.05)和空白对照组(P＜0.05)。术后3周,强骨胶囊大剂量组骨缺损消失,骨痂外直径增粗,骨痂生长更明显,强骨胶囊中剂量组和强骨胶囊小剂量组骨折处有骨性骨痂形成,丹参组和空白对照组骨痂增生不明显。强骨胶囊大剂量组和强骨胶囊中剂量组骨痂体积达到高峰且大于丹参组(P＜0.01)和空白对照组(P＜0.01),强骨胶囊大剂量组也大于强骨胶囊小剂量组(P＜0.05),强骨胶囊小剂量组大于丹参组(P＜0.05)和空白对照组(P＜0.05)。(2)HE染色结果:术后1周,强骨胶囊大剂量组成骨细胞数目多于其余各组,其它各组以血肿和炎性渗出为主要表现,软骨细胞较少。术后2周,强骨胶囊大剂量组可见软骨骨痂和骨性骨痂,软骨细胞团周边有少量编织骨形成。强骨胶囊中剂量组有少量新生骨小梁,骨折断端内外形成骨样组织。其余各组纤维性骨痂生成明显。术后3周,强骨胶囊大剂量组类骨质较多,外骨痂明显增多。强骨胶囊中剂量组骨小梁排列不规则。强骨胶囊小剂量组骨折处新生软骨已接近全部骨化。丹参组新生血管丰富,骨小梁排列紊乱。空白组纤维骨痂消失,代之以软骨骨痂与骨性骨痂。(3)免疫组化染色结果:NGF:术后1周,强骨胶囊大剂量组骨折断端纤维母细胞与少量的软骨细胞NGF阳性颗粒染色呈淡棕黄色,阳性细胞数明显多于中剂量组(P＜0.01)和强骨胶囊小剂量组(P＜0.01),强骨胶囊中剂量组多于空白对照组(P＜0.05)。术后2周,强骨胶囊中剂量组和强骨胶囊小剂量组成骨细胞胞浆内有阳性颗粒,强骨胶囊中剂量组阳性颗粒多于丹参组(P＜0.05)和空白对照组(P＜0.05)。强骨胶囊大剂量组阳性细胞数明显多于丹参组(P＜0.01)和空白对照组(P＜0.01)。术后3周,强骨胶囊中剂量组和强骨胶囊小剂量组骨痂成骨细胞染色阳性,强骨胶囊中剂量组和强骨胶囊小剂量组阳性细胞数多于大剂量组(P＜0.05)。强骨胶囊大剂量组成骨细胞轻度着色染色阳性。BMP-2:强骨胶囊大剂量组BMP-2阳性细胞数在术后1、2周时呈上升趋势,第2周时达到高峰,第3周时降低。中剂量组BMP-2阳性细胞数在术后第3周时高于其他组,与空白对照组和丹参组相比差异有显著性(P＜0.01)。bFGF:术后1周,强骨胶囊大剂量组和强骨胶囊中剂量组纤维骨痂中的成纤维细胞和血管内皮细胞,未分化间充质细胞及幼稚的成骨细胞有较均匀的棕色细颗粒状bFGF呈阳性表达,强骨胶囊中剂量组阳性细胞数明显多于强骨胶囊小剂量组(P＜0.05)、对照组(P＜0.05)和丹参组(P＜0.05)。术后2周,强骨胶囊大剂量组和强骨胶囊中剂量组在成骨细胞和幼稚的软骨细胞、新生骨基质和外骨膜成骨细胞bFGF表达阳性,阳性细胞数上升至高峰,明显多于空白对照组(P＜0.01)和丹参组(P＜0.01)。术后3周,强骨胶囊大剂量组阳性细胞数量及阳性反应程度较前明显下降,着色程度较前减弱,与空白对照组和丹参组相比有统计学意义(P＜0.05)。其它各组染色较浅,阳性细胞数明显减少。(4)血清Ca、P和ALP结果:术后1周,各组之间血清Ca浓度无明显差异(P＞0.05);术后2周,强骨胶囊中剂量组血清Ca浓度高于其他组,与丹参组相比(P＜0.01)、与对照组相比(P＜0.05),与大剂量组之间相比差异无显著性(P＞0.05)。术后3周,强骨胶囊小剂量组血清Ca浓度最高,与丹参组相比(P＜0.05)和空白对照组相比(P＜0.05),其他各组比较差异均无显著性(P＞0.05)。术后1周,各组之间血清P浓度无明显差异(P＞0.05);术后2周,强骨胶囊小剂量组血清磷浓度降低较明显,强骨胶囊大剂量组与小剂量组和空白对照组相比(P＜0.05);术后3周,各组血清P浓度均下降,强骨胶囊中剂量组下降最明显,强骨胶囊大剂量组和中剂量组与小剂量相比(P＜0.05)。术后第1、2、3周,除丹参组在第2周下降外,其余各组血清中ALP浓度均升高。术后第1周时,强骨胶囊小剂量组ALP浓度高于空白对照组(P＜0.05),其余各组差异无显著性(P＞0.05)。术后第2周时,强骨胶囊中剂量组血清ALP浓度升高明显,与丹参组相比(P＜0.01)、强骨胶囊小剂量组(P＜0.05)及空白对照组(P＜0.05),但与大剂量组之间的比较差异无显著性(P＞0.05)。大剂量组与丹参组相比(P＜0.05)。术后第3周时,大剂量组的血清ALP升高更明显,大剂量组与丹参组相比(P＜0.01)、强骨胶囊小剂量组相比(P＜0.05)及中剂量组相比(P＞0.05),而其余各组之间的比较差异无显著性(P＞0.05)。
结论
1.失神经支配骨折的修复与细胞因子的表达有关。
2.强骨胶囊能通过诱导NGF、bFGF和BMP-2的表达促进失神经支配骨折的修复。
3.强骨胶囊能改善神经元修复过程中的微环境,促进骨痂生成、生长质量,促进失神经支配骨折的愈合速度。
Objective To study the mechanism of Qianggu capsule to promote the recovery of rat's denervated fracture.Methods Male SD rats,10%Chloral Hydrate abdominal anesthesia,sever the sciatic nerve in the ischial tuberosity 0.5 cm and cut bone defect in the middle of the femur,establish denervated fracture animal model,randomly divided into Qianggu capsule large dose group(LDG),Qianggu capsule medium dose group (MDG),Qianggu capsule small dose group(SDG),Injectio Salviae Miltiorrhiae group (SMG)and control group(CG),each group have 30 rats.LDG was given Qianggu capsule 180mg/kg/d intragastric administration,once a day;MDG was given Qianggu capsule 90mg/kg/d intragastric administration,SDG was given Qianggu capsule 45mg/kg/d intragastric administration,once a day,SMG was given Injectio Salviae Miltiorrhiae 40mg/kg/d,intragastric administration,once a day;CG no disposal.In each group after one week,two weeks and three weeks cut osteotylus 1 cm from the center of the whole femoral fracture,to measure osteotylus volume.To drawe the materials from osteotylus,conventional HE staining and observe structural changes in osteotylus.NGF,BMP-2 and bFGF immunohistochemical staining,gel image analysis system to calculate each vision positive cells.Results(1)Osteotylus volume result:It is thus evident that the osteotylus volume in every group was increased in the first week of postop.,LDG and MDG increased obviously than SMG(P＜0.05)and CG (P＜0.05),SDG more than CG(P＜0.05)..In the second week of postop.,Neogenesis cartilage volume increased obviously in broken ends of fracture in LDG and SDG,external diameter of Osteotylus hyperplasia.osteotylus volume in every group increased in varied degrees.LDG hyperplasia obviously more than SMG(P＜0.01),CG (P＜0.01)and SDG(P＜0.01),MDG increased obviously than SMG(P＜0.05)and CG(P＜0.01),SDG more than SMG(P<0.05)and CG(P＜0.05).In the third week of postop.,LDG bone coloboma disappeared,extemal diameter of osteotylus more thicken,osteotylus grew more obviously,MDG and SDG have porosis in the place of fracture,SMG and CG hypercallosis not obviously.Osteotylus volume in LDG and MDG achieve peak and exceed SMG(P＜0.01)and CG(P＜0.01),LDG exceed SDG (P＜0.05),SDG exceed SMG(P＜0.05)and CG(P＜0.05).(2)HE staining Results: In the first week postop.,the amount of osteoblast in LDG more than other groups,and other groups hematoma and inflammatory exudation increased,cartilage cells less.In the second week postop.,LDG have cartilage osteotylus and bony osteotylus,cartilage cells surrounding have generated manipulus woven bone,MDG have manipulus newborn trabecular bone,osteoid tissue generated inside and outside broken ends of fracture.Other groups fiber osteotylus generate obviously.In the third week of postop.,LDG have many osteoid,osteotylus immature and low intensity,external osteotylus increased obviously and observed a lot of osteoclast and osteoclasts.MDG trabecular bone were irregular.SDG fracture ends nearly all sclerotization.SMG neovascularization richly,trabecular bone disorder,osteoclast relatively less.CG fiber osteotylus disappeared,replaced by cartilage osteotylus and boney osteotylus.(3) Immunohistochemical staining results:NGF:In the first week postop.,Fibroblast and a small amount of cartilage positive particles NGF irnmunohistochemical staining were pale brown in LDG,the number of positive cells was higher than MDG(P＜0.01)and SDG(P＜0.01).SMG more than CG(P＜0.05).In the second week postop.,MDG and SDG positive cell particles increased significantly in cytosol of osteoblast,MDG more than SMG(P＜0.05)and CG(P＜0.05).The number of positive cell in LDG was significantly more than SMG(P＜0.01)and CG(P＜0.01).In the third week postop.,MDG and SDG intraosteotylus osteoblast cells staining positive and the number of positive cells more than LDG(P＜0.05).LDG osteoblasts showed weak positive staining.BMP-2:The number of BMP-2 positive cells in LDG upward trend during 2weeks,in the second week at the peak,lower in the third weeks.BMP-2 positive cells in MDG higher than other groups,compared with CG and MG the difference was significant(P＜0.01).BFGF:In the first week postop.,LDG and MDG fibrous osteotylus fibroblasts and vascular endothelial cells,undifferentiated mesenchymal cells and naive osteoblast nucleus have uniform granular brown positive expression of bFGF,MDG positive cells was higher than the other groups,significantly higher than SDG(P＜0.05),CG(P＜0.05)and SMG(P＜0.05).In the second week postop.,LDG and MDG in osteoblasts and naive chondrocytes,new bone matrix,periosteal bone cells expression of bFGF positive,positive cells increased up to peak,significantly more than CG(P＜0.01)and SMG(P＜0.01).In the third week postop.,the number of positive cells staining and positive responses in LDG decreased obviously compared with the past,the dgree of coloring weakened than the former,compared with CG and SMG have statistical significance(P＜0.05).Other groups were less positive cells and coloring weakened.(4)Serum Ca,P and ALP results:In the first week postop.,serum Ca in every groups there was no significant difference(P＞0.05).In the second week postop.,serum Ca in MDG was higher than other groups,compared with SMG(P＜0.01)and CG(P＜0.05).compared with LDG no significant difference(P＞0.05).In the third week postop.,serum Ca in SDG was the highest,compared with SMG(P＜0.05)and CG(P＜0.05),the other groups showed no significant difference(P＞0.05).In the first week postop.,serum P in every group there was no significant difference(P＞0.05),In the second week postop.,serum P in SDG decreased obviously,LDG compared with SDG there were significant differences(P＜0.05),In the third week postop.,serum P decreased in every group,MDG decreased obviously,LDG and MDG compared with SDG(P＜0.05).Serum ALP increased in every groups during 1,2 and 3 weeks after operation except for SMG in the first two weeks fell.In the first week postop.,ALP in SDG higher than CG(P＜0.05),while the other group no significant difference (P＞0.05),In the second week postop.,serum ALP in MDG increased obviously compared with SMG(P＜0.01),SDG(P＜0.05)and CG(P＜0.05),compared with LDG the difference was no significant(P＞0.05),LDG compared with SMG(P＜0.05).In the third week postop.,serum ALP increased more significantly in LDG,LDG compared with SMG(P＜0.01),SDG(P＜0.05)and MDG(P＞0.05).There were no significant difference between the other group(P＞0.05).
Conclusion
1.The recovery of denervation fracture have relate to the expression of cytokine.
2.Qianggu capsule can promote the recovery of denervation fracture by inducing the expression of NGF,bFGF and BMP-2.
3.Qianggu capsule can improve the microenvironment in the process of neurons recovery and promote osteotylus formation,growth quality,and accelerate the healing of denervation fracture.
方法雄性SD大鼠,10%水合氯醛腹腔麻醉,在距坐骨结节0.5cm处切断坐骨神经,横形截断股骨中段,建立失神经支配骨折动物模型,造模成功后,将大鼠随机分为强骨胶囊大剂量组、强骨胶囊中剂量组、强骨胶囊小剂量组、丹参组和空白对照组,每组30只。强骨胶囊大剂量组,给予强骨胶囊180mg/kg/d灌胃,每日一次;强骨胶囊中剂量组,给予强骨胶囊90mg/kg/d灌胃,每日一次;强骨胶囊小剂量组,给予强骨胶囊45mg/kg/d;丹参组,给予丹参注射液40mg/kg/d,灌胃,每日一次;空白对照组,遭摸后不作处理。各组大鼠分别在术后1周、2周和3周取骨折中心上下各1cm全段股骨标本,测算骨痂体积。骨痂取材切片,常规HE染色,观察骨痂结构。NGF、BMP-2和bFGF免疫组织化学染色,凝胶成像分析系统计算每个视野阳性细胞数。检测血清Ca、P和ALP。
结果(1)骨痂体积测算结果:术后1周,各组骨折处均可见增粗。强骨胶囊大剂量组和强骨胶囊中剂量组骨痂体积值大于丹参组(P＜0.05)和空白对照组(P＜0.05),强骨胶囊小剂量组骨痂体积值大于空白对照组(P＜0.05)。术后2周,各组骨痂体积均有不同程度的增大。强骨胶囊大剂量组和强骨胶囊小剂量组骨折断端新生软骨量增多,骨痂外直径增生显著。强骨胶囊大剂量组骨痂体积明显大于丹参组(P＜0.01)、空白对照组(P＜0.01)和强骨胶囊小剂量组(P＜0.01),中剂量组骨痂体积明显大于空白对照组(P＜0.01)和丹参组(P＜0.05),强骨胶囊小剂量组大于丹参组(P＜0.05)和空白对照组(P＜0.05)。术后3周,强骨胶囊大剂量组骨缺损消失,骨痂外直径增粗,骨痂生长更明显,强骨胶囊中剂量组和强骨胶囊小剂量组骨折处有骨性骨痂形成,丹参组和空白对照组骨痂增生不明显。强骨胶囊大剂量组和强骨胶囊中剂量组骨痂体积达到高峰且大于丹参组(P＜0.01)和空白对照组(P＜0.01),强骨胶囊大剂量组也大于强骨胶囊小剂量组(P＜0.05),强骨胶囊小剂量组大于丹参组(P＜0.05)和空白对照组(P＜0.05)。(2)HE染色结果:术后1周,强骨胶囊大剂量组成骨细胞数目多于其余各组,其它各组以血肿和炎性渗出为主要表现,软骨细胞较少。术后2周,强骨胶囊大剂量组可见软骨骨痂和骨性骨痂,软骨细胞团周边有少量编织骨形成。强骨胶囊中剂量组有少量新生骨小梁,骨折断端内外形成骨样组织。其余各组纤维性骨痂生成明显。术后3周,强骨胶囊大剂量组类骨质较多,外骨痂明显增多。强骨胶囊中剂量组骨小梁排列不规则。强骨胶囊小剂量组骨折处新生软骨已接近全部骨化。丹参组新生血管丰富,骨小梁排列紊乱。空白组纤维骨痂消失,代之以软骨骨痂与骨性骨痂。(3)免疫组化染色结果:NGF:术后1周,强骨胶囊大剂量组骨折断端纤维母细胞与少量的软骨细胞NGF阳性颗粒染色呈淡棕黄色,阳性细胞数明显多于中剂量组(P＜0.01)和强骨胶囊小剂量组(P＜0.01),强骨胶囊中剂量组多于空白对照组(P＜0.05)。术后2周,强骨胶囊中剂量组和强骨胶囊小剂量组成骨细胞胞浆内有阳性颗粒,强骨胶囊中剂量组阳性颗粒多于丹参组(P＜0.05)和空白对照组(P＜0.05)。强骨胶囊大剂量组阳性细胞数明显多于丹参组(P＜0.01)和空白对照组(P＜0.01)。术后3周,强骨胶囊中剂量组和强骨胶囊小剂量组骨痂成骨细胞染色阳性,强骨胶囊中剂量组和强骨胶囊小剂量组阳性细胞数多于大剂量组(P＜0.05)。强骨胶囊大剂量组成骨细胞轻度着色染色阳性。BMP-2:强骨胶囊大剂量组BMP-2阳性细胞数在术后1、2周时呈上升趋势,第2周时达到高峰,第3周时降低。中剂量组BMP-2阳性细胞数在术后第3周时高于其他组,与空白对照组和丹参组相比差异有显著性(P＜0.01)。bFGF:术后1周,强骨胶囊大剂量组和强骨胶囊中剂量组纤维骨痂中的成纤维细胞和血管内皮细胞,未分化间充质细胞及幼稚的成骨细胞有较均匀的棕色细颗粒状bFGF呈阳性表达,强骨胶囊中剂量组阳性细胞数明显多于强骨胶囊小剂量组(P＜0.05)、对照组(P＜0.05)和丹参组(P＜0.05)。术后2周,强骨胶囊大剂量组和强骨胶囊中剂量组在成骨细胞和幼稚的软骨细胞、新生骨基质和外骨膜成骨细胞bFGF表达阳性,阳性细胞数上升至高峰,明显多于空白对照组(P＜0.01)和丹参组(P＜0.01)。术后3周,强骨胶囊大剂量组阳性细胞数量及阳性反应程度较前明显下降,着色程度较前减弱,与空白对照组和丹参组相比有统计学意义(P＜0.05)。其它各组染色较浅,阳性细胞数明显减少。(4)血清Ca、P和ALP结果:术后1周,各组之间血清Ca浓度无明显差异(P＞0.05);术后2周,强骨胶囊中剂量组血清Ca浓度高于其他组,与丹参组相比(P＜0.01)、与对照组相比(P＜0.05),与大剂量组之间相比差异无显著性(P＞0.05)。术后3周,强骨胶囊小剂量组血清Ca浓度最高,与丹参组相比(P＜0.05)和空白对照组相比(P＜0.05),其他各组比较差异均无显著性(P＞0.05)。术后1周,各组之间血清P浓度无明显差异(P＞0.05);术后2周,强骨胶囊小剂量组血清磷浓度降低较明显,强骨胶囊大剂量组与小剂量组和空白对照组相比(P＜0.05);术后3周,各组血清P浓度均下降,强骨胶囊中剂量组下降最明显,强骨胶囊大剂量组和中剂量组与小剂量相比(P＜0.05)。术后第1、2、3周,除丹参组在第2周下降外,其余各组血清中ALP浓度均升高。术后第1周时,强骨胶囊小剂量组ALP浓度高于空白对照组(P＜0.05),其余各组差异无显著性(P＞0.05)。术后第2周时,强骨胶囊中剂量组血清ALP浓度升高明显,与丹参组相比(P＜0.01)、强骨胶囊小剂量组(P＜0.05)及空白对照组(P＜0.05),但与大剂量组之间的比较差异无显著性(P＞0.05)。大剂量组与丹参组相比(P＜0.05)。术后第3周时,大剂量组的血清ALP升高更明显,大剂量组与丹参组相比(P＜0.01)、强骨胶囊小剂量组相比(P＜0.05)及中剂量组相比(P＞0.05),而其余各组之间的比较差异无显著性(P＞0.05)。
结论
1.失神经支配骨折的修复与细胞因子的表达有关。
2.强骨胶囊能通过诱导NGF、bFGF和BMP-2的表达促进失神经支配骨折的修复。
3.强骨胶囊能改善神经元修复过程中的微环境,促进骨痂生成、生长质量,促进失神经支配骨折的愈合速度。
Objective To study the mechanism of Qianggu capsule to promote the recovery of rat's denervated fracture.Methods Male SD rats,10%Chloral Hydrate abdominal anesthesia,sever the sciatic nerve in the ischial tuberosity 0.5 cm and cut bone defect in the middle of the femur,establish denervated fracture animal model,randomly divided into Qianggu capsule large dose group(LDG),Qianggu capsule medium dose group (MDG),Qianggu capsule small dose group(SDG),Injectio Salviae Miltiorrhiae group (SMG)and control group(CG),each group have 30 rats.LDG was given Qianggu capsule 180mg/kg/d intragastric administration,once a day;MDG was given Qianggu capsule 90mg/kg/d intragastric administration,SDG was given Qianggu capsule 45mg/kg/d intragastric administration,once a day,SMG was given Injectio Salviae Miltiorrhiae 40mg/kg/d,intragastric administration,once a day;CG no disposal.In each group after one week,two weeks and three weeks cut osteotylus 1 cm from the center of the whole femoral fracture,to measure osteotylus volume.To drawe the materials from osteotylus,conventional HE staining and observe structural changes in osteotylus.NGF,BMP-2 and bFGF immunohistochemical staining,gel image analysis system to calculate each vision positive cells.Results(1)Osteotylus volume result:It is thus evident that the osteotylus volume in every group was increased in the first week of postop.,LDG and MDG increased obviously than SMG(P＜0.05)and CG (P＜0.05),SDG more than CG(P＜0.05)..In the second week of postop.,Neogenesis cartilage volume increased obviously in broken ends of fracture in LDG and SDG,external diameter of Osteotylus hyperplasia.osteotylus volume in every group increased in varied degrees.LDG hyperplasia obviously more than SMG(P＜0.01),CG (P＜0.01)and SDG(P＜0.01),MDG increased obviously than SMG(P＜0.05)and CG(P＜0.01),SDG more than SMG(P<0.05)and CG(P＜0.05).In the third week of postop.,LDG bone coloboma disappeared,extemal diameter of osteotylus more thicken,osteotylus grew more obviously,MDG and SDG have porosis in the place of fracture,SMG and CG hypercallosis not obviously.Osteotylus volume in LDG and MDG achieve peak and exceed SMG(P＜0.01)and CG(P＜0.01),LDG exceed SDG (P＜0.05),SDG exceed SMG(P＜0.05)and CG(P＜0.05).(2)HE staining Results: In the first week postop.,the amount of osteoblast in LDG more than other groups,and other groups hematoma and inflammatory exudation increased,cartilage cells less.In the second week postop.,LDG have cartilage osteotylus and bony osteotylus,cartilage cells surrounding have generated manipulus woven bone,MDG have manipulus newborn trabecular bone,osteoid tissue generated inside and outside broken ends of fracture.Other groups fiber osteotylus generate obviously.In the third week of postop.,LDG have many osteoid,osteotylus immature and low intensity,external osteotylus increased obviously and observed a lot of osteoclast and osteoclasts.MDG trabecular bone were irregular.SDG fracture ends nearly all sclerotization.SMG neovascularization richly,trabecular bone disorder,osteoclast relatively less.CG fiber osteotylus disappeared,replaced by cartilage osteotylus and boney osteotylus.(3) Immunohistochemical staining results:NGF:In the first week postop.,Fibroblast and a small amount of cartilage positive particles NGF irnmunohistochemical staining were pale brown in LDG,the number of positive cells was higher than MDG(P＜0.01)and SDG(P＜0.01).SMG more than CG(P＜0.05).In the second week postop.,MDG and SDG positive cell particles increased significantly in cytosol of osteoblast,MDG more than SMG(P＜0.05)and CG(P＜0.05).The number of positive cell in LDG was significantly more than SMG(P＜0.01)and CG(P＜0.01).In the third week postop.,MDG and SDG intraosteotylus osteoblast cells staining positive and the number of positive cells more than LDG(P＜0.05).LDG osteoblasts showed weak positive staining.BMP-2:The number of BMP-2 positive cells in LDG upward trend during 2weeks,in the second week at the peak,lower in the third weeks.BMP-2 positive cells in MDG higher than other groups,compared with CG and MG the difference was significant(P＜0.01).BFGF:In the first week postop.,LDG and MDG fibrous osteotylus fibroblasts and vascular endothelial cells,undifferentiated mesenchymal cells and naive osteoblast nucleus have uniform granular brown positive expression of bFGF,MDG positive cells was higher than the other groups,significantly higher than SDG(P＜0.05),CG(P＜0.05)and SMG(P＜0.05).In the second week postop.,LDG and MDG in osteoblasts and naive chondrocytes,new bone matrix,periosteal bone cells expression of bFGF positive,positive cells increased up to peak,significantly more than CG(P＜0.01)and SMG(P＜0.01).In the third week postop.,the number of positive cells staining and positive responses in LDG decreased obviously compared with the past,the dgree of coloring weakened than the former,compared with CG and SMG have statistical significance(P＜0.05).Other groups were less positive cells and coloring weakened.(4)Serum Ca,P and ALP results:In the first week postop.,serum Ca in every groups there was no significant difference(P＞0.05).In the second week postop.,serum Ca in MDG was higher than other groups,compared with SMG(P＜0.01)and CG(P＜0.05).compared with LDG no significant difference(P＞0.05).In the third week postop.,serum Ca in SDG was the highest,compared with SMG(P＜0.05)and CG(P＜0.05),the other groups showed no significant difference(P＞0.05).In the first week postop.,serum P in every group there was no significant difference(P＞0.05),In the second week postop.,serum P in SDG decreased obviously,LDG compared with SDG there were significant differences(P＜0.05),In the third week postop.,serum P decreased in every group,MDG decreased obviously,LDG and MDG compared with SDG(P＜0.05).Serum ALP increased in every groups during 1,2 and 3 weeks after operation except for SMG in the first two weeks fell.In the first week postop.,ALP in SDG higher than CG(P＜0.05),while the other group no significant difference (P＞0.05),In the second week postop.,serum ALP in MDG increased obviously compared with SMG(P＜0.01),SDG(P＜0.05)and CG(P＜0.05),compared with LDG the difference was no significant(P＞0.05),LDG compared with SMG(P＜0.05).In the third week postop.,serum ALP increased more significantly in LDG,LDG compared with SMG(P＜0.01),SDG(P＜0.05)and MDG(P＞0.05).There were no significant difference between the other group(P＞0.05).
Conclusion
1.The recovery of denervation fracture have relate to the expression of cytokine.
2.Qianggu capsule can promote the recovery of denervation fracture by inducing the expression of NGF,bFGF and BMP-2.
3.Qianggu capsule can improve the microenvironment in the process of neurons recovery and promote osteotylus formation,growth quality,and accelerate the healing of denervation fracture.
引文
[1]Hietaniemi K,Peltonen J,Paavolainen P.An experimental model for non-union in rats[J].Injury,1995,26(10):323-325.
[2]Cheng H,Cao Yihai,Olson L.Spinal cord repair in adult paralegic rats partial restoration of hind limb function[J].Science,1996,273(7):510-513.
[3]Perkinds FR,skirving AP.Callus formation and the mte of healing of femoml fractures in patients with head injuries etal[J].J Bone Joint surg(Br)1987,69:521-524.
[4]D.R.Sumner,etal.Enhancement of bone in growth by transforming growth factor-β[J].The Journal of Bone and Joint Surgery,1995,77-A(8):1135-1147.
[5]Cornell CN.Newest factors in fracture healing[J].Clin Orthop,1992,277:297.
[6]刘宏泽,王文瑞.丹参与骨碎补注射液防治激素诱发股骨头坏死的实验研究[J].中国骨伤,2003,16(12):726-728.
[7]王华松,黄琼霞,许申明.骨碎补对骨折愈合中血生化指标及TGF-β_1表达的影响[J].中医正骨,2001,13(5):6-8.
[8]常新,侯志明,柴田恭明,等.碱性磷酸酶和骨钙素在成骨过程中表达的定量研究[J].华西口腔医学杂志,2005,23(5):424.
[9]Cho TJ,Gerstenfeld LC,Einhorn TA.Differential temporal expressionof members of the Transforming growth factor-β superfamily during murine fracture healing[J].J Bone Miner Res,2002,17(3):513-520.
[10]洪宁,胡信雷,耿春辉.活血通络中药复方对家兔骨折后血清碱性磷酸酶、钙、磷的影响[J].淮海医药,2007,25(5):421.
[11]樊粤光,黄永明,曾意荣,等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用[J].中国中医骨伤科杂志,2003,111(6):6.
[12]刘金文,黄永明,许少健,等.中药骨碎补对大鼠骨髓破骨细胞体外培养的影响[J].中医研究,2005,18(7):5-7.
[13]姚建华,时述山,李亚非.神经生长因子对骨折愈合影响的研究进展[J].中国矫形外科杂志,2000,7(10):996-998.
[14]Schuijers JA,Ward AR,Grills BL.Nerve growth factor improves fracture healing in rats[J].In proceedings of the Australian physiological and pharmacological society,1995,26(1):98.
[15]Grills BL,Schuijers JA.Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone[J].Acta Orthopscand,1998,69:415-419.
[16]刘文革,管文超,廖伟光,等.神经生长因子(NGF)对骨折愈合影响的初步临床观察[J].中国实用医药杂志,2007,2(13):27.
[17]张映,张英起,吴勇杰,等.鼠坐骨神经损伤后mNGF对再生的影响[J].第四军医大学学报,2003,24(13):1194.
[18]陈燕涛,何清,刘存礼.神经生长因子治疗周围神经损伤的前瞻性研究[J].中华创伤骨科杂志,2006,8(8):746.
[19]李德霞,任琳,杨晓红,等.老年2型糖尿病患者心理障碍及护理对策[J].中原医刊,2003,30(2):60.
[20]Lustman PJ.Psychiatric illness in diabetes mellitus relationshipto symptoms and glucose Control[J].J Nerv Ment Dis,1986,174(12):736.
[21]Clogd CE.The relationship between stress and the development of diabetic complication[J].Diabetes Meal,1991,8(2):146.
[22]Lustman PJ,Griffith LS,Gare JA,etal.Depression inadult swith diabetes[J].Diabetes Care,1992,15(11):1631.
[23]关智宇,付红河,刘长利,等.生长因子对骨折愈合研究进展[J].实用中西医结合临床,2004,4(2):72.
[24]王英慧.成纤维细胞的生物学特性及其成骨作用的研究进展[J].大同医学专科学校学报,2006,2:31.
[25]Galvin KA,Oorschot DE Continuous low dose treatment with brain derived neurotrophic factor or neurotrophin protectsstriatal medium spiny neurons from mild neonatal hypoxiais chemia a stereological study[J].Neuroscience,2003,118(4):10-31.
[26]潘杏兰.碱性成纤维细胞生长因子骨诱导作用的研究进展[J].国外医学生物医学工程分册,2005,28(3):158.
[27]李亚非,时述山,刘树清,等.骨痂中骨形态蛋白发生和碱性成纤维细胞生长因子基因表达与骨折愈合[J].中国矫形外科杂志,1998,5(5):352-353.
[28]Madsen JE,Hukkanen M,Aune AK Basran I,etal.Fractute healing and callus in nervation after peripheral nerve resection in rats[J].Clin Orthop,1998,(351):230-40.
[1]李顺祥,龙勉,张志光,等.骨碎补的研究进展[J].中国中医药信息杂志,2002,11(9):75-78.
[2]ZHENG R X,YANG J SH.The chemical and bioactive studies on flavanol compounds[J].World Notes on Plant Medicine,2005,20(2):58-61.1046.
[3]吴新安,赵毅民.骨碎补化学成分研究[J].中国中药杂志,2005,30(6):443-444.
[4]刘剑刚,谢雁鸣,赵晋宁,等.骨碎补总黄酮胶囊对实验性骨质疏松症和镇痛作用的影响[J].中国实验方剂学杂志,2004,10(5):31.
[5]刘剑刚,谢雁鸣,邓文龙,等.骨碎补总黄酮抗炎作用的实验研究[J].中国天然药物,2004,2(4):232.
[6]GONG X J,LI Y M,AN B P,etal.Effect of total flavonoids of rhizoma Drynariae on experimental knee osteoart hritis[J].Chin.J.N at.Med,2006,4(13):215-218.
[7]CAI CH SH,XIAO P,ZHANG Y,etal.Effect of Gusuibu zong huang tong on level of TNF-α and IL-6 in macrophagocyte[J].Orthopedic Journal of China,2006,14(15):1185-1187.
[8]XU ZH W,ZHANGJ X,TAN G Q,etai.lnfluence of Gusuibu(Drynaria aronii)-eateracted liquid on invitro osteogenetic differenctiation of rabbit marrow stormal celis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2006,18(6):15-17.
[9]XIE Y M,Q1N L L,DENG W L,etal.Study on mechanism of effect sof total flavone of rhizoma Drynariae on osteoblasts cultured in vitro[J].China Journal of Traditional Chinese Medicine and Pharmacy.2006,10(3):12
[10]李军,贾天柱,张颖.骨碎补的研究概况[J].中药材,1999,22(5):2631.
[11]张桂茹,王重远,刘莉.中药骨碎补对卡那霉素耳毒性预防效果的实验研究[J].吉林大学学报(医学版),1993,02:164-165.
[12]蒋文功,出蒲照国,方敬爱,等.骨碎补类黄酮对氯化汞所致的急性肾衰竭大鼠模型的保护作用[J].中国中西医结合肾病杂志,2006,02:75.
[13]Sun J S,Lin C Y,Dong GC,et al.The effect ofgu-Sui-Bu(drynar-ia fortunei J Sm)on bone cell activities[J].Biornaterials,2002,23(16):3377.
[14]Wonq RW,Rabie AB.Systemic effect of crude extract from rhizome of Drynaria fortunei on bone formation in mice[J].Phytother Res,2006,20(4):313-315.
[15]Jeonq JC,Lee JW,Yoon CH,et al.lnhibitory activity of Drynariaerhizoma extracts on cathepsin having bone resorption activity[J].Immunopharmacol Immunotoxicol,2004,26(3):373-385.
[16]高焱.骨碎补总黄酮治疗骨折延迟愈合和骨不连[J].中医正骨,2007,19(7):11.
[17]王华松,黄琼霞,许申明.骨碎补对骨折愈合中血生化指标及TGF-β_1表达的影响[J].中医正骨,2001,13(5):6.
[18]殷军,王大为,李发美,等.几种生药的提取部分对成骨细样细胞的增殖作用[J].沈阳药科大学学报,2001,18(4):278-282.
[19,20]董福慧,郑军,程伟.骨碎补对骨愈合过程中相关基因表达的影响[J].中国中西医结合杂志,2003,23(7):518-521.
[21]Jeonq JC,Lee JW,Yoon CH,etal.Effects of Drynariae rhizoma on theproliferation of human bone cells and the immunomodulatory activity[J].Pharmacol Res,2005,51(2):125-136.
[22]谢雁鸣,秦林林,向东,等.淫羊藿、菟丝子总黄酮对成骨细胞体外培养影响的比较研究[J].中国中医药信息杂志,2005,12(7):22.
[23]谢雁鸣,秦林林,邓文龙,等.骨碎补总黄酮对成骨细胞体外培养作用的机制研究[J].中华中医药杂志,2005,20(3):161.
[24]刘金文,黄永明,许少健,等.中药骨碎补对大鼠骨髓破骨细胞体外培养的影响[J].中医研究,2005,18(7):5-6.
[25]樊粤光,黄永明,曾意荣,等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用[J].中国中医骨伤科杂志,2003,111(6):4-6.
[26]唐琪,陈莉丽,严杰.骨碎补提取物促小鼠成骨细胞株MC3T32E1细胞增殖、分化和钙化作用的研究[J].中国中药杂志,2004,29(2):165.
[27]徐展望,张建新,李军,等.骨碎补提取液对兔骨髓基质细胞增殖影响的实验研究[J].中医正骨,2005,17(4):1-3.
[28]邓展生,张璇,邹冬青,等.骨碎补各种提取成分对人骨髓间充质干细胞的影响[J].中国现代医学杂志,2005,15(16):2426.
[29]徐展望,张建新,李军.骨碎补提取液对兔骨髓基质细胞增殖的影响[J].中医正骨2005,17(4):1.
[30]邓展生,张璇,邹冬青,等.骨碎补有效成分柚皮甙对人骨髓间充质干细胞的影响[J].湘南学院学报(自然科学版),2005,7(4):5.
[31]徐展望,张建新,谭国庆,等.中药骨碎补提取液对兔骨髓基质细胞体外成骨分化的影响[J].中医正骨2006,18(6):15.
[32]谢雁鸣,许勇钢,赵晋宁,等.骨碎补总黄酮对去卵巢大鼠骨密度和细胞因子IL-6、IL-4、TNF-α水平的影响[J].中国中医基础医学杂志,2004,10(1):34-37.
[33]冀孝如,强骨胶囊治疗老年骨质疏松症的临床观察[J].山西医药杂志,2006,35(4):342.
[34]谢雁鸣,鞠大宏,赵晋宁.骨碎补总黄酮对去卵巢大鼠骨密度和骨组织形态计量学影响[J].中国中药杂志,2004,29(4):343.
[35]廖悦华,梁琼,王卓,等.中药骨碎补对去睾丸骨质疏松症动物模型的影响[J].中国骨质疏松杂志,2007,13(4):277.
[36]刘剑刚,谢雁鸣,徐哲,等.骨碎补总黄酮的活血化瘀作用及对实验性微循环障碍和骨质疏松症的影响[J].中国骨质疏松杂志,2006,12(1):46.
[37]单硕,周光.强骨胶囊治疗原发性骨质疏松症的临床疗效[J].西北药学杂志,2006,21(4):177.
[38]王和鸣,田金洲,彭淑莲,等.强骨胶囊治疗骨质疏松早期骨量减少的临床观察[J].中国骨伤,2003,16(11):692-694.
[39]王健,张维康,王朝晖.强骨胶囊治疗绝经后骨质疏松症28例[J].医药导报,2007,26(11):1325-1326.
[40]王和鸣,葛继荣,田金洲,等.强骨胶囊(骨碎补总黄酮)治疗骨质疏松症骨痛的疗效观察[J].中国中医骨伤科杂志,2005,13(6):38.
[1]陈凌,高建民,张彦定.骨形态发生蛋白成骨机理及应用研究现状[J].福建医药杂志,2004,26(1):119-121.
[2]邹天彪,闫景龙,付海亮,等.复合骨形态发生蛋白BMP的微小颗粒骨修复兔桡骨缺损的实验研究[J].中华创伤骨科杂志,2004,6(6):661-665.
[3]卢卫忠,唐康来,朱庆和,等.TGF-β和BMP对胎兔颅骨成骨样细胞增殖和分化相互作用的实验研究[J].中华创伤骨科杂志,2004,6(4):450-452.
[4]程瑞芳,郭若霖,温学红,等.人骨形成蛋白和地塞米松对不同来源成骨细胞的作用[J].天津医药,2004,32(4):193-196.
[5]刘锋,张柳,程爱国.骨折愈合的分子生物学研究进展[J].华北煤炭医学院学报,2004,6(4):457-459.
[6]于博,田京,靳安民.骨形态发生蛋白的研究现状及在脊柱融合中的应用[J].中国临床康复,2003,7(20):2856-2857.
[7]Carina Forslund,Per Aspenberg,etal.Impmved healing of Transected rabbit Achilles Tendon after a single injection of cartilage-derived morphogenetic prootein-2[J].The American journal of sports medicine,2003,31:555-559.
[8]Radovan Mihelic,Marko Pecina.Mislav Jelic,et al.Bonemorphogenetie protein-7(osteogenic protein-1)promotes tendon graftintegration in Anterior Cruciate Ligament reconstruction in sheep[J].The American Journal of Sports Medicine,2004,32:1619-1625.
[9]郭静芹,徐进亮,梁爱琴,等.脑和脊髓损伤对骨折股骨骨痂中NGF表达影响[J].青岛大学医学院学报,2006,42(1):34-36.
[10]马骋,苟三怀,肖海军,等.神经生长因子对失神经状态下大鼠骨折愈合的影响[J].第二军医大学学报,2007,5:474.
[11]夏群,苗军,张继东,等.周围神经系统对骨折愈合影响的实验研究[J].中华创伤骨科杂志,2003,5(3):233.
[12]刘宇鹏,赵德伟,吕德成等.神经生长因子在大鼠骨折部位的表达[J].中国临床康复,2006,17:107.
[13]王新,宋跃明,裴福兴等.神经损伤对大鼠股骨骨折愈合影响观察[J].中国矫形外科杂志,2005,20:51-53.
[14]傅文学,马建敏,万斌,等.兔坐骨神经细胞微囊化处理移植至大鼠损伤脊髓对神经生长因子表达变化的影响[J].中国临床康复,2006,17:7-9.
[15]戴寿荣,高润,孔喜良,等.神经生长因子对失神经支配大鼠骨小梁形态计量的影响[J].中国康复医学杂志,2003,8:32-33.
[16]顾晓松,丁斐,徐炜岚,等.大鼠坐骨神经损伤后NGF基因表达的变化[J].解剖学报,2000,S1:45-47.
[17]刘文革,管文超,廖伟光,等.神经生长因子(NGF)对骨折愈合影响的初步临床观察[J].中国实用医药,2007,13:27-29.
[18]苗军,夏群,张继东,等.失神经对大鼠胫骨骨折愈合影响作用的实验研究[J].中国矫形外科杂志,2003,12:41-43.
[19]高润,阮德明.神经损伤对骨代谢影响的实验研究[J].中国实用神经疾病杂志,2006,6:55-57.
[20]彭锐,程杰,邹阳.生骨注射液对大鼠骨折愈合过程中bFGF表达的影响[J].湖北中医杂志,2007,7:5-6.
[21]曾晖,杜靖远,郑启新,等.碱性成纤维细胞生长因子对成骨细胞增殖和分化的影响[J].实用医学杂志,2002,2:126-128.
[22]王立平,党耕町.碱性成纤维细胞生长因子在骨愈合过程中的表达与合成[J].中华骨科杂志,1999,8:38-40.
[23]初同伟,王正国,朱佩芳.VEGF在骨折愈合过程中对Ⅷ因子相关抗原表达变化影响的实验研究[J].第三军医大学学报,2002,24(2):132.
[24]李恒,沈霖,李丽琴,等.阿胶强骨口服液对骨折愈合过程VEGF和FGF-2表达的影响[J].中国中医骨伤科杂志2006,14(4):38.
[25]赵宝东,赵洪涛,赵艳,等.TGF-p促进骨折愈合的实验研究[J].锦州医学院学报,2001,22(2):4.
[26]卢卫忠,唐康来,朱庆和,等.不同剂量转化生长因子β对兔尺骨骨折愈合作用的研究[J].第三军医大学学报,2003,25(11):980.
[27]卢卫忠,唐康来,杨柳,等.不同时间给予转化生长因子β对兔骨折愈合作用的研究[J].第三军医大学学报,2003,25(9):753.
[28]马昕,黄钢勇,姜建元,等.不同神经损伤对骨折前期愈合影响的实验研究[J].中国矫形外科杂志.2005,13(10):761.
[29]刘春蓉,苗军,夏群.股神经坐骨神经切断对大鼠胫骨骨折愈合早期影响的骨计量学观察[J].中国临床康复,2004,9(38):90.
[30]秦煜,裴国献,吴岚晓.抗神经生长因子抗体对SD大鼠股骨发育的作用[J].中国临床康复,2003,2:206-207.
[2]Cheng H,Cao Yihai,Olson L.Spinal cord repair in adult paralegic rats partial restoration of hind limb function[J].Science,1996,273(7):510-513.
[3]Perkinds FR,skirving AP.Callus formation and the mte of healing of femoml fractures in patients with head injuries etal[J].J Bone Joint surg(Br)1987,69:521-524.
[4]D.R.Sumner,etal.Enhancement of bone in growth by transforming growth factor-β[J].The Journal of Bone and Joint Surgery,1995,77-A(8):1135-1147.
[5]Cornell CN.Newest factors in fracture healing[J].Clin Orthop,1992,277:297.
[6]刘宏泽,王文瑞.丹参与骨碎补注射液防治激素诱发股骨头坏死的实验研究[J].中国骨伤,2003,16(12):726-728.
[7]王华松,黄琼霞,许申明.骨碎补对骨折愈合中血生化指标及TGF-β_1表达的影响[J].中医正骨,2001,13(5):6-8.
[8]常新,侯志明,柴田恭明,等.碱性磷酸酶和骨钙素在成骨过程中表达的定量研究[J].华西口腔医学杂志,2005,23(5):424.
[9]Cho TJ,Gerstenfeld LC,Einhorn TA.Differential temporal expressionof members of the Transforming growth factor-β superfamily during murine fracture healing[J].J Bone Miner Res,2002,17(3):513-520.
[10]洪宁,胡信雷,耿春辉.活血通络中药复方对家兔骨折后血清碱性磷酸酶、钙、磷的影响[J].淮海医药,2007,25(5):421.
[11]樊粤光,黄永明,曾意荣,等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用[J].中国中医骨伤科杂志,2003,111(6):6.
[12]刘金文,黄永明,许少健,等.中药骨碎补对大鼠骨髓破骨细胞体外培养的影响[J].中医研究,2005,18(7):5-7.
[13]姚建华,时述山,李亚非.神经生长因子对骨折愈合影响的研究进展[J].中国矫形外科杂志,2000,7(10):996-998.
[14]Schuijers JA,Ward AR,Grills BL.Nerve growth factor improves fracture healing in rats[J].In proceedings of the Australian physiological and pharmacological society,1995,26(1):98.
[15]Grills BL,Schuijers JA.Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone[J].Acta Orthopscand,1998,69:415-419.
[16]刘文革,管文超,廖伟光,等.神经生长因子(NGF)对骨折愈合影响的初步临床观察[J].中国实用医药杂志,2007,2(13):27.
[17]张映,张英起,吴勇杰,等.鼠坐骨神经损伤后mNGF对再生的影响[J].第四军医大学学报,2003,24(13):1194.
[18]陈燕涛,何清,刘存礼.神经生长因子治疗周围神经损伤的前瞻性研究[J].中华创伤骨科杂志,2006,8(8):746.
[19]李德霞,任琳,杨晓红,等.老年2型糖尿病患者心理障碍及护理对策[J].中原医刊,2003,30(2):60.
[20]Lustman PJ.Psychiatric illness in diabetes mellitus relationshipto symptoms and glucose Control[J].J Nerv Ment Dis,1986,174(12):736.
[21]Clogd CE.The relationship between stress and the development of diabetic complication[J].Diabetes Meal,1991,8(2):146.
[22]Lustman PJ,Griffith LS,Gare JA,etal.Depression inadult swith diabetes[J].Diabetes Care,1992,15(11):1631.
[23]关智宇,付红河,刘长利,等.生长因子对骨折愈合研究进展[J].实用中西医结合临床,2004,4(2):72.
[24]王英慧.成纤维细胞的生物学特性及其成骨作用的研究进展[J].大同医学专科学校学报,2006,2:31.
[25]Galvin KA,Oorschot DE Continuous low dose treatment with brain derived neurotrophic factor or neurotrophin protectsstriatal medium spiny neurons from mild neonatal hypoxiais chemia a stereological study[J].Neuroscience,2003,118(4):10-31.
[26]潘杏兰.碱性成纤维细胞生长因子骨诱导作用的研究进展[J].国外医学生物医学工程分册,2005,28(3):158.
[27]李亚非,时述山,刘树清,等.骨痂中骨形态蛋白发生和碱性成纤维细胞生长因子基因表达与骨折愈合[J].中国矫形外科杂志,1998,5(5):352-353.
[28]Madsen JE,Hukkanen M,Aune AK Basran I,etal.Fractute healing and callus in nervation after peripheral nerve resection in rats[J].Clin Orthop,1998,(351):230-40.
[1]李顺祥,龙勉,张志光,等.骨碎补的研究进展[J].中国中医药信息杂志,2002,11(9):75-78.
[2]ZHENG R X,YANG J SH.The chemical and bioactive studies on flavanol compounds[J].World Notes on Plant Medicine,2005,20(2):58-61.1046.
[3]吴新安,赵毅民.骨碎补化学成分研究[J].中国中药杂志,2005,30(6):443-444.
[4]刘剑刚,谢雁鸣,赵晋宁,等.骨碎补总黄酮胶囊对实验性骨质疏松症和镇痛作用的影响[J].中国实验方剂学杂志,2004,10(5):31.
[5]刘剑刚,谢雁鸣,邓文龙,等.骨碎补总黄酮抗炎作用的实验研究[J].中国天然药物,2004,2(4):232.
[6]GONG X J,LI Y M,AN B P,etal.Effect of total flavonoids of rhizoma Drynariae on experimental knee osteoart hritis[J].Chin.J.N at.Med,2006,4(13):215-218.
[7]CAI CH SH,XIAO P,ZHANG Y,etal.Effect of Gusuibu zong huang tong on level of TNF-α and IL-6 in macrophagocyte[J].Orthopedic Journal of China,2006,14(15):1185-1187.
[8]XU ZH W,ZHANGJ X,TAN G Q,etai.lnfluence of Gusuibu(Drynaria aronii)-eateracted liquid on invitro osteogenetic differenctiation of rabbit marrow stormal celis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2006,18(6):15-17.
[9]XIE Y M,Q1N L L,DENG W L,etal.Study on mechanism of effect sof total flavone of rhizoma Drynariae on osteoblasts cultured in vitro[J].China Journal of Traditional Chinese Medicine and Pharmacy.2006,10(3):12
[10]李军,贾天柱,张颖.骨碎补的研究概况[J].中药材,1999,22(5):2631.
[11]张桂茹,王重远,刘莉.中药骨碎补对卡那霉素耳毒性预防效果的实验研究[J].吉林大学学报(医学版),1993,02:164-165.
[12]蒋文功,出蒲照国,方敬爱,等.骨碎补类黄酮对氯化汞所致的急性肾衰竭大鼠模型的保护作用[J].中国中西医结合肾病杂志,2006,02:75.
[13]Sun J S,Lin C Y,Dong GC,et al.The effect ofgu-Sui-Bu(drynar-ia fortunei J Sm)on bone cell activities[J].Biornaterials,2002,23(16):3377.
[14]Wonq RW,Rabie AB.Systemic effect of crude extract from rhizome of Drynaria fortunei on bone formation in mice[J].Phytother Res,2006,20(4):313-315.
[15]Jeonq JC,Lee JW,Yoon CH,et al.lnhibitory activity of Drynariaerhizoma extracts on cathepsin having bone resorption activity[J].Immunopharmacol Immunotoxicol,2004,26(3):373-385.
[16]高焱.骨碎补总黄酮治疗骨折延迟愈合和骨不连[J].中医正骨,2007,19(7):11.
[17]王华松,黄琼霞,许申明.骨碎补对骨折愈合中血生化指标及TGF-β_1表达的影响[J].中医正骨,2001,13(5):6.
[18]殷军,王大为,李发美,等.几种生药的提取部分对成骨细样细胞的增殖作用[J].沈阳药科大学学报,2001,18(4):278-282.
[19,20]董福慧,郑军,程伟.骨碎补对骨愈合过程中相关基因表达的影响[J].中国中西医结合杂志,2003,23(7):518-521.
[21]Jeonq JC,Lee JW,Yoon CH,etal.Effects of Drynariae rhizoma on theproliferation of human bone cells and the immunomodulatory activity[J].Pharmacol Res,2005,51(2):125-136.
[22]谢雁鸣,秦林林,向东,等.淫羊藿、菟丝子总黄酮对成骨细胞体外培养影响的比较研究[J].中国中医药信息杂志,2005,12(7):22.
[23]谢雁鸣,秦林林,邓文龙,等.骨碎补总黄酮对成骨细胞体外培养作用的机制研究[J].中华中医药杂志,2005,20(3):161.
[24]刘金文,黄永明,许少健,等.中药骨碎补对大鼠骨髓破骨细胞体外培养的影响[J].中医研究,2005,18(7):5-6.
[25]樊粤光,黄永明,曾意荣,等.骨碎补提取液对体外分离破骨细胞性骨吸收的作用[J].中国中医骨伤科杂志,2003,111(6):4-6.
[26]唐琪,陈莉丽,严杰.骨碎补提取物促小鼠成骨细胞株MC3T32E1细胞增殖、分化和钙化作用的研究[J].中国中药杂志,2004,29(2):165.
[27]徐展望,张建新,李军,等.骨碎补提取液对兔骨髓基质细胞增殖影响的实验研究[J].中医正骨,2005,17(4):1-3.
[28]邓展生,张璇,邹冬青,等.骨碎补各种提取成分对人骨髓间充质干细胞的影响[J].中国现代医学杂志,2005,15(16):2426.
[29]徐展望,张建新,李军.骨碎补提取液对兔骨髓基质细胞增殖的影响[J].中医正骨2005,17(4):1.
[30]邓展生,张璇,邹冬青,等.骨碎补有效成分柚皮甙对人骨髓间充质干细胞的影响[J].湘南学院学报(自然科学版),2005,7(4):5.
[31]徐展望,张建新,谭国庆,等.中药骨碎补提取液对兔骨髓基质细胞体外成骨分化的影响[J].中医正骨2006,18(6):15.
[32]谢雁鸣,许勇钢,赵晋宁,等.骨碎补总黄酮对去卵巢大鼠骨密度和细胞因子IL-6、IL-4、TNF-α水平的影响[J].中国中医基础医学杂志,2004,10(1):34-37.
[33]冀孝如,强骨胶囊治疗老年骨质疏松症的临床观察[J].山西医药杂志,2006,35(4):342.
[34]谢雁鸣,鞠大宏,赵晋宁.骨碎补总黄酮对去卵巢大鼠骨密度和骨组织形态计量学影响[J].中国中药杂志,2004,29(4):343.
[35]廖悦华,梁琼,王卓,等.中药骨碎补对去睾丸骨质疏松症动物模型的影响[J].中国骨质疏松杂志,2007,13(4):277.
[36]刘剑刚,谢雁鸣,徐哲,等.骨碎补总黄酮的活血化瘀作用及对实验性微循环障碍和骨质疏松症的影响[J].中国骨质疏松杂志,2006,12(1):46.
[37]单硕,周光.强骨胶囊治疗原发性骨质疏松症的临床疗效[J].西北药学杂志,2006,21(4):177.
[38]王和鸣,田金洲,彭淑莲,等.强骨胶囊治疗骨质疏松早期骨量减少的临床观察[J].中国骨伤,2003,16(11):692-694.
[39]王健,张维康,王朝晖.强骨胶囊治疗绝经后骨质疏松症28例[J].医药导报,2007,26(11):1325-1326.
[40]王和鸣,葛继荣,田金洲,等.强骨胶囊(骨碎补总黄酮)治疗骨质疏松症骨痛的疗效观察[J].中国中医骨伤科杂志,2005,13(6):38.
[1]陈凌,高建民,张彦定.骨形态发生蛋白成骨机理及应用研究现状[J].福建医药杂志,2004,26(1):119-121.
[2]邹天彪,闫景龙,付海亮,等.复合骨形态发生蛋白BMP的微小颗粒骨修复兔桡骨缺损的实验研究[J].中华创伤骨科杂志,2004,6(6):661-665.
[3]卢卫忠,唐康来,朱庆和,等.TGF-β和BMP对胎兔颅骨成骨样细胞增殖和分化相互作用的实验研究[J].中华创伤骨科杂志,2004,6(4):450-452.
[4]程瑞芳,郭若霖,温学红,等.人骨形成蛋白和地塞米松对不同来源成骨细胞的作用[J].天津医药,2004,32(4):193-196.
[5]刘锋,张柳,程爱国.骨折愈合的分子生物学研究进展[J].华北煤炭医学院学报,2004,6(4):457-459.
[6]于博,田京,靳安民.骨形态发生蛋白的研究现状及在脊柱融合中的应用[J].中国临床康复,2003,7(20):2856-2857.
[7]Carina Forslund,Per Aspenberg,etal.Impmved healing of Transected rabbit Achilles Tendon after a single injection of cartilage-derived morphogenetic prootein-2[J].The American journal of sports medicine,2003,31:555-559.
[8]Radovan Mihelic,Marko Pecina.Mislav Jelic,et al.Bonemorphogenetie protein-7(osteogenic protein-1)promotes tendon graftintegration in Anterior Cruciate Ligament reconstruction in sheep[J].The American Journal of Sports Medicine,2004,32:1619-1625.
[9]郭静芹,徐进亮,梁爱琴,等.脑和脊髓损伤对骨折股骨骨痂中NGF表达影响[J].青岛大学医学院学报,2006,42(1):34-36.
[10]马骋,苟三怀,肖海军,等.神经生长因子对失神经状态下大鼠骨折愈合的影响[J].第二军医大学学报,2007,5:474.
[11]夏群,苗军,张继东,等.周围神经系统对骨折愈合影响的实验研究[J].中华创伤骨科杂志,2003,5(3):233.
[12]刘宇鹏,赵德伟,吕德成等.神经生长因子在大鼠骨折部位的表达[J].中国临床康复,2006,17:107.
[13]王新,宋跃明,裴福兴等.神经损伤对大鼠股骨骨折愈合影响观察[J].中国矫形外科杂志,2005,20:51-53.
[14]傅文学,马建敏,万斌,等.兔坐骨神经细胞微囊化处理移植至大鼠损伤脊髓对神经生长因子表达变化的影响[J].中国临床康复,2006,17:7-9.
[15]戴寿荣,高润,孔喜良,等.神经生长因子对失神经支配大鼠骨小梁形态计量的影响[J].中国康复医学杂志,2003,8:32-33.
[16]顾晓松,丁斐,徐炜岚,等.大鼠坐骨神经损伤后NGF基因表达的变化[J].解剖学报,2000,S1:45-47.
[17]刘文革,管文超,廖伟光,等.神经生长因子(NGF)对骨折愈合影响的初步临床观察[J].中国实用医药,2007,13:27-29.
[18]苗军,夏群,张继东,等.失神经对大鼠胫骨骨折愈合影响作用的实验研究[J].中国矫形外科杂志,2003,12:41-43.
[19]高润,阮德明.神经损伤对骨代谢影响的实验研究[J].中国实用神经疾病杂志,2006,6:55-57.
[20]彭锐,程杰,邹阳.生骨注射液对大鼠骨折愈合过程中bFGF表达的影响[J].湖北中医杂志,2007,7:5-6.
[21]曾晖,杜靖远,郑启新,等.碱性成纤维细胞生长因子对成骨细胞增殖和分化的影响[J].实用医学杂志,2002,2:126-128.
[22]王立平,党耕町.碱性成纤维细胞生长因子在骨愈合过程中的表达与合成[J].中华骨科杂志,1999,8:38-40.
[23]初同伟,王正国,朱佩芳.VEGF在骨折愈合过程中对Ⅷ因子相关抗原表达变化影响的实验研究[J].第三军医大学学报,2002,24(2):132.
[24]李恒,沈霖,李丽琴,等.阿胶强骨口服液对骨折愈合过程VEGF和FGF-2表达的影响[J].中国中医骨伤科杂志2006,14(4):38.
[25]赵宝东,赵洪涛,赵艳,等.TGF-p促进骨折愈合的实验研究[J].锦州医学院学报,2001,22(2):4.
[26]卢卫忠,唐康来,朱庆和,等.不同剂量转化生长因子β对兔尺骨骨折愈合作用的研究[J].第三军医大学学报,2003,25(11):980.
[27]卢卫忠,唐康来,杨柳,等.不同时间给予转化生长因子β对兔骨折愈合作用的研究[J].第三军医大学学报,2003,25(9):753.
[28]马昕,黄钢勇,姜建元,等.不同神经损伤对骨折前期愈合影响的实验研究[J].中国矫形外科杂志.2005,13(10):761.
[29]刘春蓉,苗军,夏群.股神经坐骨神经切断对大鼠胫骨骨折愈合早期影响的骨计量学观察[J].中国临床康复,2004,9(38):90.
[30]秦煜,裴国献,吴岚晓.抗神经生长因子抗体对SD大鼠股骨发育的作用[J].中国临床康复,2003,2:206-207.